Pain free? Meet Cas­sa­va, the newest Alzheimer’s play­er on Nas­daq

Pain Ther­a­peu­tics is bury­ing its name and the world of hurt around its four-time re­ject opi­oid, Re­moxy, in search of bet­ter for­tunes in an­oth­er — but cer­tain­ly no eas­i­er — dis­ease area.

Re­brand­ing it­self as Cas­sa­va Sci­ences (com­plete with a new tick­er $SA­VA), the com­pa­ny for­mer­ly known as $PTIE claims it is now go­ing all in on a new ap­proach to Alzheimer’s dis­ease amid a fo­cus shift from anal­gesics to treat­ments for neu­rode­gen­er­a­tive ail­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER